Literature DB >> 7925870

Prognostic factors and survival in malignant pleural mesothelioma.

T Van Gelder1, R A Damhuis, H C Hoogsteden.   

Abstract

Malignant pleural mesothelioma is a lethal disease and little is known about prognostic factors. The prognostic significance of age, stage of disease, gender and histological subtype was studied in 167 new cases of cytologically (15%) or histologically (85%) proven malignant pleural mesothelioma in the Rotterdam area, during the period 1987-1989. Median survival of all patients was 242 days. Univariate analysis identified age, stage and histopathological subtype as significant prognostic factors, which was confirmed in multivariate analysis. Median survival rates for patients < 65, 65-74 and > or = 75 yrs were 359, 242 and 131 days, respectively. Patients with Stage I disease had a median survival of 359 days compared to 147 and 112 days, respectively, for patients with Stage II and the combination of Stages III and IV. Mixed histopathological subtype (190 days) was less favourable than sarcomatous (207 days) and epithelial (252 days) subtypes. Using a Cox proportional hazard model in patients with malignant pleural mesothelioma, age, histological subtype and stage were identified as independent prognostic factors. These prognostic factors should be taken into account when starting or evaluating treatment studies.

Entities:  

Mesh:

Year:  1994        PMID: 7925870

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

Review 1.  Statement on malignant mesothelioma in the United Kingdom.

Authors: 
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis "Podhrastovi" in ten-year period (from 1998 to 2007).

Authors:  Vesna Cukić; Aida Ustamujić; Vladimir Lovre; Hasan Zutić; Sadika Genjac; Mina Masić-Zecević
Journal:  Bosn J Basic Med Sci       Date:  2008-11       Impact factor: 3.363

Review 4.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

5.  Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Authors:  Lucian R Chirieac; Yin P Hung; Wai Chin Foo; Matthias D Hofer; Paul A VanderLaan; William G Richards; David J Sugarbaker; Raphael Bueno
Journal:  Cancer       Date:  2019-08-07       Impact factor: 6.860

6.  Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Authors:  Robert Ryan Meyerhoff; Chi-Fu Jeffrey Yang; Paul J Speicher; Brian C Gulack; Matthew G Hartwig; Thomas A D'Amico; David H Harpole; Mark F Berry
Journal:  J Surg Res       Date:  2015-01-29       Impact factor: 2.192

7.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

Review 8.  Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.

Authors:  J Green; Y Dundar; S Dodd; R Dickson; T Walley
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

9.  Factors that impact susceptibility to fiber-induced health effects.

Authors:  Jennifer E Below; Nancy J Cox; Naomi K Fukagawa; Ari Hirvonen; Joseph R Testa
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

10.  Prognosis and prognostic factors of patients with mesothelioma: a population-based study.

Authors:  S van der Bij; H Koffijberg; J A Burgers; P Baas; M J van de Vijver; B A J M de Mol; K G M Moons
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.